Diosmin - instructions for use, doses, side effects, contraindications

Excipients: gelatin - 7.800 mg, sodium carboxymethyl starch (type A) 19.400 mg, magnesium stearate 9.700 mg, microcrystalline cellulose up to 970,000 mg.

Shell composition: opedrai II 85F240012 Pink - 30,000 mg: polyvinyl alcohol 12,000 mg, macrogol-3350-7,314 mg, iron dye red oxide 0.120 mg, iron oxide oxide yellow 0.066 mg, talc 4,440 mg, titanium dioxide 6,060 mg.

Description:

Capsule-shaped, biconvex tablets with a risk on one side, covered with a film coat from light pink to pink. On the cross-section - the core of the tablet from gray-yellow to gray-brown color, it is allowed to impart a lighter and darker shade.

Pharmacotherapeutic group:angioprotective agent

ATX: & nbsp

C.05.C.A.03 Diosmin

Pharmacodynamics:

Diosmin belongs to the group of bioflavonoids, it has phlebotonic (reduces the extensibility of veins,increases tone vein (dose-dependent effect), reduces venous stasis), improves lymphatic drainage (increases the tone and frequency of contraction of the lymph capillaries, increases their functional density reduces lymphatic pressure), improves (increases capillary resistance (dose-dependent effect), reduces their permeability) It reduces the adhesion of leukocytes to the venous wall and their migration into tissues paravenoznye, improves oxygen diffusion and perfusion in the skin tissue, possesses anti-inflammatory action.

Strengthens the vasoconstrictive effect of adrenaline, norepinephrine, blocks the production of free radicals, the synthesis of prostaglandins and thromboxane.

Pharmacokinetics:

Diosmin is rapidly absorbed from the gastrointestinal tract. It is detected in the blood plasma 2 hours after ingestion. The bioavailability of the drug after oral administration is approximately 40-57,9%. Part of the drug is metabolized by bacteria cecum to form hippuric and benzoic acids.

The maximum concentration in the blood plasma is reached after 5 hours after administration. The drug accumulates in all layers of the wall of the vena cava and saphenous veins of the lower extremities,to a lesser extent - in the kidneys, liver and lungs and other tissues. The volume of distribution of the drug is 62.1 liters. The maximum selective accumulation of diosmin and / or its metabolites in the wall of venous vessels is noted 9 hours after administration and is maintained for 96 hours.

Diosmin is rapidly metabolized in the liver. The main metabolite is hydroxyphenylpropionic acid. Metabolites of diosmina are excreted mainly by kidneys in the form of conjugates with glucuronic acid. 79% of the received diosmina is excreted by the kidneys, 11% by the intestine, 2.4%% - with bile. Enterohepatic circulation of the drug is noted. After taking a radioactive isotope labeled diosmin, approximately 86% of the drug is excreted by the kidneys and intestines within 48 hours.

Indications:

- Varicose veins of the lower extremities (elimination of symptoms);

- xRonal lymphovenous insufficiency of the lower extremities (elimination of symptoms);

- aboutsevere hemorrhoids (in complex therapy to relieve symptoms);

- Mr.microcirculation (for example, with idiopathic edema).

Contraindications:

- Hypersensitivity to the components of the drug;

- children's age till 18 years (experience of application is limited);

- Pregnancy (I trimester) and the period of breastfeeding (experience of use is limited).

Pregnancy and lactation:

Experience with the drug in pregnant women is limited. There were no reports of any adverse reactions with the use of diosmin in pregnant women in clinical practice. In experimental studies, there was no teratogenic effect of diosmine on the course of pregnancy, embryo-fetal and postnatal development. Nevertheless, for safety reasons, the use of the drug in the first trimester of pregnancy is contraindicated. If it is necessary to use the drug during the II and III trimesters of pregnancy, it is recommended to consult a doctor beforehand.

During breastfeeding, taking the drug is not recommended. there is no data on the penetration of diosmin into breast milk.

Dosing and Administration:

The drug is intended for oral administration.

With varicose veins of the lower extremities and chronic lymphovenous insufficiency

The drug is used for 1 tablet a day in the morning on an empty stomach. The duration of therapy is usually 2 months.In severe forms of chronic lymphovenous insufficiency (swelling, pain, cramps, etc.), treatment may be longer (the total duration of continuous therapy should not exceed three to four months). Course of drug treatment Diosmin repeat after 2-3 months.

For the treatment of chronic lymphovenous insufficiency during the II and III trimester of pregnancy, the drug is used 1 tablet 1 time per day. The duration of therapy is not more than 30 days. It is necessary to stop taking the drug 2-3 weeks before the birth.

With an exacerbation of hemorrhoids

The drug is used on 2-3 tablets a day during meals for 7 days. Further, if necessary, you can continue taking the drug 1 tablet 1 time per day for 1-2 months.

With violations of microcirculation

The drug is used for 1 tablet a day in the morning on an empty stomach. The duration of therapy is usually 1-2 months.

If you miss one or more of the medications, you must continue to use the drug in the usual mode and in a regular dose.

Side effects:

The frequency of side effects is determined in accordance with the WHO classification of adverse drug reactions by the frequency of occurrence: very often more than 1/10, often more than 1/100 and less than 1/10, infrequently more than 1/1000 and less than 1/100, more than 1/10000 and less than 1/1000,very rarely - less than 1/10000, including isolated cases; an unknown frequency (it is impossible to determine the frequency of occurrence of an undesired reaction from available data).

From the gastrointestinal tract: often - nausea, vomiting, diarrhea (diarrhea), dyspeptic disorders, heartburn, constipation; infrequently - colitis.

From the central nervous system: rarely - headache, dizziness.

From the skin and subcutaneous fat: rarely - skin rashes, itching;

Allergic reactions: rarely - hives, unknown frequency - isolated edema of the face, lips, eyelids; in exceptional cases - angioedema (Quincke's edema).

General disorders: rarely - malaise.

If any of the side effects listed in the instruction are aggravated, or you notice any other side effects, not specified in the instructions, inform the doctor about it.

Overdose:

Cases of overdose are not described. Given the wide therapeutic range of diosmosis, the risk of intoxication with an overdose is insignificant. The specific antidote is unknown.

If an overdose occurs, seek medical help immediately!

Interaction:

Clinically significant interactions of diosmine with other drugs are not described.

Special instructions:

Treatment of acute hemorrhoids is carried out in conjunction with other drugs. In the absence of a rapid clinical effect, it is recommended to consult a proctologist, if necessary, to conduct an additional examination and adjust the therapy.

In cases of venous circulation disorders (varicose veins of the lower extremities, chronic lymphovenous insufficiency of the lower extremities), the maximum effect of treatment is provided by combining therapy with lifestyle changes: it is desirable to avoid prolonged stay in an upright position,

reduce excess body weight. In some cases, the improvement of blood circulation is facilitated by wearing special stockings (compression jersey).

The experience of using diosmin in children younger than 18 years is not enough.

If there is no reduction or if symptoms worsen, consult a doctor!

Do not exceed the maximum periods and recommended doses of the drug without consulting your doctor!

Effect on the ability to drive transp. cf. and fur:

The drug does not affect the ability to drive vehicles and mechanisms.

Form release / dosage:

Film-coated tablets, 600 mg.

Packaging:

For 5, 10 tablets in a contour mesh box made of polyvinylchloride film and aluminum foil printed lacquered.

10, 20, 30, 40, 50, 60 or 100 tablets in cans of polyethylene terephthalate for medicinal products sealed with caps screwed on with first opening control or by a "push-turn" system of polypropylene or polyethylene or polypropylene cans for drugs sealed with lids stretched with the control of the first opening of polyethylene or cans of polypropylene for drugs, sealed with lids pulled with the control of the first opening of high-pressure polyethylene.

One jar or 1, 2, 3, 4, 5 or 10 contour mesh packages together with the instruction for use are placed in a cardboard package (bundle).

Storage conditions:

In the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiration date.

Terms of leave from pharmacies:Without recipe

Registration number:LP-003889

Date of registration:07.10.2016

Expiration Date:07.10.2021

The owner of the registration certificate:ATOLL, LLC ATOLL, LLC Russia

Manufacturer: & nbsp

OZONE, LLC Russia

Representation: & nbspOZONE LLC OZONE LLC Russia

Information update date: & nbsp28.10.2016

Illustrated instructions

Instructions

Diosmin (Diosmin)